Latest Conference Articles

A unique program that focuses on specific neighborhoods in Philadelphia with high hepatitis C and HIV/AIDS infection rates provides free testing, works with local leaders to destigmatize testing, and connects infected individuals with needed health care services.

Researchers have had little success in developing an HIV cure, but recent studies involving gene therapy, immune-based therapy, reactivation of the immune system, and "very early" treatment have produced promising results.

Due to improvements in treatment and other factors, the number of HIV-positive patients over age 50 is growing rapidly. With their greater risk for serious comorbidities such as depression and addiction, these patients represent a unique challenge for clinicians and caregivers.

Mary Lynn McPherson, PharmD, BCPS, CPE, FASPE, shows healthcare professionals how to apply an equianalgesic opioid dosing chart to 12 complicated patient cases requiring an opioid switch.

Fifteen posters presented at PAINWeek 2013 demonstrate the efficacy, safety, and tolerability of a novel controlled-release combination oxycodone-acetaminophen analgesic in acute pain patients.

Post-hoc analysis of phase III clinical study results finds lubiprostone doesn't interfere with the analgesic effect of opioids in chronic non-cancer pain patients with opioid-induced constipation.

Although clinical psychiatrist Michael E. Schatman, PhD, CPE, formerly "beat the hell out of the opioid industry," he spent an hour on the PAINWeek stage supporting his new belief that "maybe it's time to stop fighting."

Two literature reviews of single-arm open-label (OL), open-label extension (OLE), and epidemiologic studies with a duration of six months or more provide evidence that long-term opioid therapy improves pain scores in chronic non-cancer pain patients.

In a cohort of family medicine physicians, researchers found a strong inverse relationship between confidence and comfort toward opioid prescribing and concern about negative consequences.

As the doctor shopping rate for immediate-release single entity oxycodone increased by 9 percent, reformulated extended-release OxyContin's doctor shopping rate fell by 40 percent.

Lisa M. McElhaney addresses the limited education, awareness, and prevention of bullying within pain management practices.

Commander John J. Burke details how pain management practitioners can adequately protect themselves from prescription drug diverters without hurting their legitimate patients.

Jennifer E. Bolen, JD, says it's the responsibility of physicians - not labs - to ensure drug testing reports comply with federal and state guidelines in the event of an audit.

Michael R. Clark, MD, MPH, MBA, outlines the vulnerabilities that put patients with acute pain at risk of transitioning into new chronic pain.

A panel of three experts from the legal side of pain management said investigations into prescribers after patient deaths resulting from opioid overdose are rare and overblown.

News and updates about PAINWeek 2013.

News and updates about USCA 2013.

Study results support early treatment, even in patients with a high CD4 count.

Researchers discussed new HIV vaccine developments in protecting antibodies capable of neutralizing many different strains of the virus and reviewed the comorbidity of HIV and hepatitis C virus (HCV).

HIV-infected patients face increased risk of myocardial infarction, as well as higher risk for ART-associated dyslipidemia and insulin resistance.

A panel of experts discuss information from late-breaking abstracts presented at IAS 2013, including information on the two patients who remain HIV-free following stem cell transplant.

Two male patients with prolonged HIV infection who received hematopoietic stem cell transplants still remain virus-free several consecutive weeks after their antiretroviral treatments were discontinued this spring.

Panel discussion of study results presented at IAS 2013 focusing on strategies for using antiretroviral therapy (ART) in patients with HIV who are ART-naïve or who have failed previous therapies.

A new report says a broader base of funders committed to sustained support of HIV prevention research is need to ensure continued progress in the fight to end the AIDS epidemic.

As pre-exposure prophylaxis (PrEP) remains at the forefront of HIV prevention research, clinical trial investigators provided an update on recent oral and topical PrEP efficacy studies at the second plenary session of the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013), held June 30 to July 3 in Kuala Lumpur, Malaysia.

Consolidated guidelines from the World Health Organization recommend starting treatment when a patient's CD4 count falls below 500, and also recommend a new first-line ART regimen.

By adopting a comprehensive set of case management policies for the care of diabetic and hyperglycemic patients, Johns Hopkins Hospital improved in-hospital mortality rate, reduced length of stay, and reduced hyperglycemia.

Exposure to insulin glargine and metformin did not cause increased risk of cancer or worse cancer outcomes.

Results of a three-year trial of the experimental GLP-1 receptor agonist albiglutide showed that it had a better effect on HbA1c, fasting blood glucose, and body weight than two comparator drugs.

Prescription-strength doses of vitamin D improve highly prevalent comorbidities among diabetic women, such as depression and pain, and also improve risk factors such as excess weight and high blood pressure.